Approach to Patients with Multiple Myeloma after BCMA targeted Therapy

B-cell maturation antigen (BCMA) – directed therapies - including bispecific antibodies, chimeric antigen receptor T-cell therapy, and antibody–drug conjugates - have significantly improved outcomes for patients with relapsed or refractory multiple myeloma but with finite responses in the majority of patients. With an increasing number of patients being treated in earlier lines, there is an urgent need for guidelines on best treatment strategy following BCMA exposure. This review summarizes current understanding of resistance mechanisms to BCMA-directed therapies and examines available evidence on treatment approaches for patients relapsing after BCMA-targeted therapy. Emerging data suggest that resistance to BCMA-directed therapy arises through multiple mechanisms, including BCMA antigen loss or mutation, T-cell exhaustion, and an immunosuppressive tumor microenvironment. Sequential use of BCMA-targeted therapies can still induce responses, although response durability is typically shorter compared with BCMA-naïve populations. Recent studies highlight the importance of treatment sequencing and timing, with longer intervals between BCMA-directed therapies associated with improved outcomes. Target-switch strategies, particularly therapies directed against alternative antigens such as GPRC5D or FcRH5, have demonstrated promising activity in patients previously exposed to BCMA-targeted therapies. Management of multiple myeloma after BCMA-directed therapy represents an evolving clinical challenge. While sequential BCMA-targeted therapies remain a potential option in selected patients, strategies incorporating a BCMA-free interval, switching to alternative antigen targets, and the development of multi-antigen immunotherapies are likely to play an increasing role. Further clinical and translational studies are needed to define optimal sequencing strategies and improve outcomes for this growing patient population.

Authors

Institutions

Publication Details

Journal
Current Hematologic Malignancy Reports
Published
2026-11-14
DOI
https://doi.org/10.1007/s11899-026-00793-2
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Approach to Patients with Multiple Myeloma after BCMA targeted Therapy

Hanne Marie Norseth, Rakesh Popat, Fredrik Schjesvold
Current Hematologic Malignancy Reports
Multiple Myeloma Research and Treatments
article

Approach to Patients with Multiple Myeloma after BCMA targeted Therapy

Hanne Marie Norseth, Rakesh Popat, Fredrik Schjesvold
article en

Abstract

B-cell maturation antigen (BCMA) – directed therapies - including bispecific antibodies, chimeric antigen receptor T-cell therapy, and antibody–drug conjugates - have significantly improved outcomes for patients with relapsed or refractory multiple myeloma but with finite responses in the majority of patients. With an increasing number of patients being treated in earlier lines, there is an urgent need for guidelines on best treatment strategy following BCMA exposure. This review summarizes current understanding of resistance mechanisms to BCMA-directed therapies and examines available evidence on treatment approaches for patients relapsing after BCMA-targeted therapy. Emerging data suggest that resistance to BCMA-directed therapy arises through multiple mechanisms, including BCMA antigen loss or mutation, T-cell exhaustion, and an immunosuppressive tumor microenvironment. Sequential use of BCMA-targeted therapies can still induce responses, although response durability is typically shorter compared with BCMA-naïve populations. Recent studies highlight the importance of treatment sequencing and timing, with longer intervals between BCMA-directed therapies associated with improved outcomes. Target-switch strategies, particularly therapies directed against alternative antigens such as GPRC5D or FcRH5, have demonstrated promising activity in patients previously exposed to BCMA-targeted therapies. Management of multiple myeloma after BCMA-directed therapy represents an evolving clinical challenge. While sequential BCMA-targeted therapies remain a potential option in selected patients, strategies incorporating a BCMA-free interval, switching to alternative antigen targets, and the development of multi-antigen immunotherapies are likely to play an increasing role. Further clinical and translational studies are needed to define optimal sequencing strategies and improve outcomes for this growing patient population.

Current Hematologic Malignancy ReportsVol. 21(1)
Oslo University Hospital (NO), University College London Hospitals NHS Foundation Trust (GB)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon